Skip to content

Switzerland English logo

Main menu
    • About us
    • Our vision
    • Our values
    • Environmental, Social & Governance (ESG)
    • Organon GmbH – Transparenz
  • Our areas of focus
  • Media/Press
  • Join our team
  • Contact Us

Back
Change Language
  • Contact Us
  • Deutsch
  • Français
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:
Organon Illustration zweier Hände, eine hält eine Weltkugel, die andere ein Businessgebäude

Transparency is Our Standard Practice

We share information openly about our cooperation with patient organizations, healthcare professionals, and medical institutions.

Organon Illustration einer Frau, die Formulare ausfüllt

ScienceIndustries Pharma Code of Cooperation

As a member of ScienceIndustries (Chemistry Pharma Life Sciences Commercial Association), we publish our donations to patient organizations and to healthcare professionals (listed below) in accordance with the Pharma Cooperation Code:

  • Grants in the areas of research and development, including payments for participation in studies, clinical trials, and in prospective non-interventional studies
  • Grants associated with training events, for example conference or participation fees and the costs of travel and accommodation
  • Donations
  • Lecture and consulting fees
  • Sponsorships, for example financial contributions to large professional conferences or external training events
ScienceIndustries Pharma Code of CooperationOpens a new window

Overview of our donations to medical professionals and patient organizations

Grants to physicians and other healthcare professionals

Publication reports:

  • Report 2021 (PDF)
  • Report 2022 (PDF)
  • Report 2023 (PDF)
  • Report 2024 (PDF)

Methodological notes:

  • Methodological Notes 2021 (PDF)
  • Methodological Notes 2022 (PDF) 
  • Methodological Notes 2023 (PDF)
  • Methodological Notes 2024 (PDF)

Grants to patient organizations

No grants were made to patient organizations in the 2021 reporting period.

No grants were made to patient organizations in the 2022 reporting period.

No grants were made to patient organizations in the 2023 reporting period.

No grants were made to patient organizations in the 2024 reporting period.


CH-NON-110142 – June 2025

Switzerland English logo
  • Publisher
  • Terms of Use
  • AGB
  • Cookie Policy
  • Privacy Policy
© 2025 Organon group of companies. All rights reserved.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept